INmune Bio, Inc. (NASDAQ:INMB) Q3 2023 Earnings Conference Call November 1, 2023 4:30 PM ET Company Participants David Moss - Chief Financial Officer RJ Tesi - Chief Executive Officer Mark Lowdell - Chief Scientific Officer Conference Call Participants Joel Beatty - Baird Tom Shrader - BTIG Daniel Carlson - Tailwinds Research Operator Greetings and welcome to the INmune Bio Third Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38793 INMUNE BIO INC. (Exact name of registrant as specified in its charter) (Address of principal executive of ice) (Zip code) (858) 964-3720 (Registrant's ...

INmune Bio, Inc. (NASDAQ:INMB) Q2 2023 Earnings Conference Call August 7, 2023 4:30 PM ET Company Participants David Moss - Chief Financial Officer RJ Tesi - Chief Executive Officer & Chief Medical Officer Conference Call Participants Joel Beatty - Baird Operator Greetings, and welcome to the INmune Bio Second Quarter 2023 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded. A transcript will follow within 24 hours of this conference call. At this time, it is my pleasure ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 INMUNE BIO INC. (Exact name of registrant as specified in its charter) (State of incorporation) (I.R.S. Employer Nevada 47-5205835 Identification No.) | Large accelerated filer | ☐ | Acceler ...

INmune Bio, Inc. (NASDAQ:INMB) Q1 2023 Earnings Conference Call May 3, 2023 4:30 PM ET Company Participants David Moss - Chief Financial Officer RJ Tesi - Chief Executive Officer Mark Lowdell - Chief Scientific Officer Conference Call Participants Tom Shrader - BTIG Daniel Carlson - Tailwinds Research Operator Good day and welcome to the INmune Bio First Quarter 2023 Earnings Conference Call. All participants will be in a listen-only mode. [Operator Instructions] Please note today's event is being recorded. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 INMUNE BIO INC. (Exact name of registrant as specified in its charter) (State of incorporation) (I.R.S. Employer David Moss 225 NE Mizner Blvd., Suite 640 Boca Raton, FL 33432 (Address of p ...

INmune Bio, Inc. (NASDAQ:INMB) Q4 2022 Earnings Conference Call March 2, 2023 4:30 PM ET Company Participants David Moss - CFO RJ Tesi - CEO CJ Barnum - Head of Neuroscience Mark Lowdell - Chief Scientific Officer Conference Call Participants Jason McCarthy - Maxim Group Tom Shrader - BTIG Daniel Carlson - Tailwinds Research Operator Greetings, and welcome to the INmune Bio Fourth Quarter and Full Year 2022 Earnings Call. This conference will be recorded. A brief question-and-answer session will follow the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2022 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission file number: 001-38793 INMUNE BIO INC. (Exact name of registrant as specified in its charter) Nevada 47-5205835 (State or other jurisdiction of inco ...

INmune Bio, Inc. (NASDAQ:INMB) Q3 2022 Results Conference Call November 2, 2022 4:30 PM ET Company Participants David Moss - Chief Financial Officer Dr. RJ Tesi - Chief Executive Officer Dr. CJ Barnum - Head of Neuroscience Dr. Mark Lowdell - Chief Scientific Officer Conference Call Participants Tom Shrader - BTIG Mayank Mamtani - B. Riley Securities Daniel Carlson - Tailwinds Research Operator Greetings, and welcome to the INmune Bio Third Quarter 2022 Earnings Call. [Operator Instructions]. At this time, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 INMUNE BIO INC. (Exact name of registrant as specified in its charter) (State of incorporation) (I.R.S. Employer Nevada 47-5205835 Identification No.) FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2022 David Moss 225 NE Mizner Blvd., Su ...